scholarly journals Economic impact of Enterosgel® in the hospital treatment of diarrhoeal syndromes associated with different disease conditions

ABOUTOPEN ◽  
2021 ◽  
Vol 8 (1) ◽  
pp. 99-105
Author(s):  
Roberto Ravasio ◽  
Paola Raimondo
Keyword(s):  
Infectious Diseases ◽  
Hospital Admissions ◽  
Cost Minimization ◽  
Secondary Analysis ◽  
Standard Of Care ◽  
Inpatient Admission ◽  
Hospital Treatment ◽  
Hospital Stays ◽  
Pass Through ◽  
The Cost

Background: Enterosorbents are orally administered materials which pass through the gut where they bind various substances. In a randomized clinical trial, the efficacy and safety of enterosorbent Enterosgel® in the treatment of non-infectious diseases with diarrhoea have been proved. Objective: To assess the cost impact of Enterosgel® in the treatment of hospitalized patients with non-infectious diseases with diarrhoea adopting a cost/minimization approach. Methods: A cost analysis was conducted considering the hospital’s perspective. The analysis compared the treatment costs (drugs and hospital stays) of Enterosgel® in addition to the standard of care (SoC) to SoC alone. The main analysis focused on the comparison between the two therapeutic strategies regarding the economic valorization of hospital stays, while the secondary analysis estimated the hospital organizational efficiency with regard to the annual bed turnover. Results: Reducing the duration of inpatient admission, compared to SoC alone, Enterosgel® in addition to SoC let the hospital obtain a greater valorization of the hospital stays (range: € 68.54-€ 558.60). The shorter duration of inpatient admission results in an increased number of hospital admissions per year. For example, assuming a 10-bed ward, the total hospital annual gain would be € 82,616. Conclusions: Enterosgel® in addition to SoC is cost saving, allowing the hospital to achieve greater efficiency in managing patients with non-infectious diseases with diarrhoea.

Cost minimization analysis of the treatment of distal radial fractures in the elderly

2018 ◽  
Vol 100-B (2) ◽  
pp. 205-211 ◽  
Author(s):  
E. Q. Pang ◽  
J. Truntzer ◽  
L. Baker ◽  
A. H. S. Harris ◽  
M. J. Gardner ◽  
...  
Keyword(s):  
Cost Minimization ◽  
Secondary Analysis ◽  
The Elderly ◽  
Distal Radial Fracture ◽  
Radial Fracture ◽  
Distal Radial Fractures ◽  
Payer Perspective ◽  
Chi Squared ◽  
The Mean ◽  
The Cost

Aims The aim of this study was to test the null hypothesis that there is no difference, from the payer perspective, in the cost of treatment of a distal radial fracture in an elderly patient, aged > 65 years, between open reduction and internal fixation (ORIF) and closed reduction (CR). Materials and Methods Data relating to the treatment of these injuries in the elderly between January 2007 and December 2015 were extracted using the Humana and Medicare Advantage Databases. The primary outcome of interest was the cost associated with treatment. Secondary analysis included the cost of common complications. Statistical analysis was performed using a non-parametric t-test and chi-squared test. Results Our search yielded 8924 patients treated with ORIF and 5629 patients treated with CR. The mean cost of an uncomplicated ORIF was more than a CR ($7749 versus $2161). The mean additional cost of a complication in the ORIF group was greater than in the CR group ($1853 versus $1362). Conclusion These findings show that there are greater payer fees associated with ORIF than CR in patients aged > 65 years with a distal radial fracture. CR may be a higher-value intervention in these patients. Cite this article: Bone Joint J 2018;100-B:205–11.

scholarly journals Evaluation of restricted antibiotic utilization and cost-minimization analysis in a tertiary care hospital in India

2021 ◽  
Vol 7 (2) ◽  
pp. 116
Author(s):  
Dhakchinamoorthi Krishna Kumar ◽  
Mani Swapna ◽  
Srinivasan Kanmani ◽  
Varghese Varsha ◽  
Nair V. Vidya
Keyword(s):  
Infectious Diseases ◽  
Cost Minimization ◽  
Pharmacoeconomic Analysis ◽  
Statistical Significance ◽  
Unit Cost ◽  
Tertiary Care ◽  
Care Hospital ◽  
Cost Minimization Analysis ◽  
The Cost ◽  
Mean Cost

<p class="abstract"><strong>Background:</strong> Antibiotic resistance is a major menace to public health and treatment of several infectious diseases, also associated with an economic burden to society.  Pharmacoeconomic analysis of antibiotic usage and cost-minimization analysis provides better and low-cost drug selection for the patients.</p><p class="abstract"><strong>Methods:</strong> The study was conducted as a cross-sectional, observational analysis of restricted antibiotics in the prescriptions (n= 191). Cost minimization analysis was conducted for the restricted antibiotics alone. The drug costs of prescribed brands were compared with the least cost brands, and the percentage cost difference was calculated and compared by student paired ‘t’ test. P&lt;0.05 considered statistical significance.  </p><p class="abstract"><strong>Results:</strong> The average age of the patients was found to be 58.1±18.3 (Mean±SD) years, and most of the restricted antibiotics were prescribed for the treatment of hospital-acquired infections 71.7%. Meropenem was prescribed highly 29.8% followed by imipenem (28.8%) and colistin (12%). The major reason for starting restricted antibiotics was found to be infectious diseases (27.7%). The cost-minimization analysis showed that the total unit cost for caspofungin (₹1,85,000 or $2523.40) was found to be higher followed by meropenem (₹1,29,800) in the prescriptions. The mean cost of actually prescribed restricted antibiotics was found to be ₹68,338±61,332 (Mean±SD). The lowest mean cost of restricted antibiotics was found to be ₹32,223±31,082 (p&lt;0.05).</p><p class="abstract"><strong>Conclusions:</strong> Pharmacoeconomic cost-minimization analysis was a useful tool for clinical pharmacist in the selection of appropriate antibiotics and minimizing the burden of the cost of the drugs, it provides a better outcome in patients while using restricted antibiotics with infectious disease.</p>

Cost-minimization analysis of drugs used in the treatment of Asthma and COPD diseases in India

2020 ◽  
Vol 15 ◽  
Author(s):  
Billu Payal ◽  
Anoop Kumar ◽  
Harsh Saxena
Keyword(s):  
Generic Drugs ◽  
Cost Minimization ◽  
Cost Savings ◽  
Chronic Obstructive ◽  
Pulmonary Medicine ◽  
Potential Cost ◽  
Maximum Cost ◽  
Cost Minimization Analysis ◽  
Cost Variation ◽  
The Cost

Background: Asthma and Chronic Obstructive Pulmonary Diseases (COPD) are well known respiratory diseases affecting millions of peoples in India. In the market, various branded generics, as well as generic drugs, are available for their treatment and how much cost will be saved by utilizing generic medicine is still unclear among physicians. Thus, the main aim of the current investigation was to perform cost-minimization analysis of generic versus branded generic (high and low expensive) drugs and branded generic (high expensive) versus branded generic (least expensive) used in the Department of Pulmonary Medicine of Era Medical University, Lucknow for the treatment of asthma and COPD. Methodology: The current index of medical stores (CIMS) was referred for the cost of branded drugs whereas the cost of generic drugs was taken from Jan Aushadi scheme of India 2016. The percentage of cost variation particularly to Asthma and COPD regimens on substituting available generic drugs was calculated using standard formula and costs were presented in Indian Rupees (as of 2019). Results: The maximum cost variation was found between the respules budesonide high expensive branded generic versus least expensive branded generic drugs and generic versus high expensive branded generic. In combination, the maximum cost variation was observed in the montelukast and levocetirizine combination. Conclusion: In conclusion, this study inferred that substituting generic antiasthmatics and COPD drugs can bring potential cost savings in patients.

Compensation based on active power filters – The cost minimization

2015 ◽  
Vol 267 ◽  
pp. 648-654 ◽  
Author(s):  
Marcin Maciążek ◽  
Dariusz Grabowski ◽  
Marian Pasko ◽  
Michał Lewandowski
Keyword(s):  
Cost Minimization ◽  
Active Power ◽  
Active Power Filters ◽  
Power Filters ◽  
The Cost

scholarly journals Exploring the Cost-Benefit of Vaccines for Infectious Diseases in Slaughter Pig Production

2003 ◽  
Vol 44 (Suppl 1) ◽  
pp. P55
Author(s):  
Nils Toft ◽  
Anders R Kristensen ◽  
Erik Jørgensen
Keyword(s):  
Infectious Diseases ◽  
Cost Benefit ◽  
Pig Production ◽  
The Cost

Physical Development and Medical History of Children Who Were Treated Antenatally With Corticosteroids to Prevent Respiratory Distress Syndrome: A 10- to 12-Year Follow-up

PEDIATRICS ◽  
1990 ◽  
Vol 86 (1) ◽  
pp. 65-70 ◽  
Author(s):  
H. Smolders-de Haas ◽  
J. Neuvel ◽  
B. Schmand ◽  
p. E. Treffers ◽  
J. G. Koppe ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Medical History ◽  
Distress Syndrome ◽  
Hospital Admissions ◽  
Controlled Trial ◽  
Ophthalmological Examination ◽  
Double Blind ◽  
History Of

Potential side effects of antenatal administration of corticosteroids to prevent neonatal respiratory distress syndrome were studied in 10- to 12-year-old children whose mothers had participated in a randomized, double-blind, placebo-controlled trial of betamethasone. The children had a general physical examination; parents were interviewed about the medical history of their child with special attention to infectious diseases; growth data were collected; and a developmental neurological examination, an ophthalmological examination, and a lung function test were conducted. In the corticosteroid group significantly more hospital admissions because of infectious diseases during the first years of life were reported. On the other variables no differences between the corticoid and the placebo groups were found.

Prescribing practice: an overview of the principles

2021 ◽  
Vol 30 (17) ◽  
pp. 1016-1022
Author(s):  
Aby Mitchell ◽  
Reuben Pearce
Keyword(s):  
Hospital Admissions ◽  
Healthcare Services ◽  
Valuable Resource ◽  
Long Term Conditions ◽  
Legal Principles ◽  
Nurse Prescribing ◽  
Prescribing Practice ◽  
Hospital Stays

Nurse prescribing has become a well-established aspect of advanced clinical practice working alongside key NHS principles and drivers to address the increasing complexities in patient care and the demands on the health service. Prescribing practice is governed by ethical and legal principles to ensure a holistic patient-centred approach. It has been recognised as a valuable resource that could effectively transform healthcare services to reduce hospital admissions and long hospital stays and improve the quality of life for patients with long-term conditions and multiple comorbidities. This article will provide an overview of prescribing practice.

scholarly journals Proposal of resources optimization in the hospital treatment of heart failure by an increased utilization of cardiac rehabilitation

2016 ◽  
Vol 66 (4) ◽  
Author(s):  
Tommaso Diaco ◽  
Geremia Milanesi ◽  
Daniela Zaniboni ◽  
Massimo Gritti ◽  
Gianna Zavatteri ◽  
...  
Keyword(s):  
Cardiac Rehabilitation ◽  
Average Length ◽  
Mean Value ◽  
Hospital Treatment ◽  
Utilization Rate ◽  
Average Length Of Stay ◽  
Use Of Resources ◽  
Acute Patient ◽  
The Cost ◽  
Acute Patients

weight on social cost. An improved resources utilization could promote a reduction of the new hospitalization and a of medical costs. Working hypotesis: To analyze a model of increased utilization of our Cardiac Rehabilitation (CR) Unit, aiming at improving the cost/profit ratio through a better use of resources and a better assignment of care. With a reduction of average length of stay in the Operative Units for acute patients, we could promote a demand of post-acute hospitalization of 950.7 days of hospitalization that could be assigned to Cardiologic Rehabilitation Unit. Results: With the transfer of patients the utilization rate of CR would increase to 97%. With a mean period in bed of 15.3 days we could hospitalize 62 additional patients and the total margin of contribution would became positive: 69.817 euro. The break even analysis applied to costs and returns of the Unit shows a further indication to increase the hospitalization number in CR Unit with patients transfered from acute patient units. Under the same costs the recovery of efficiency leads to a reduction of variable costs. In the same time there is an increase of returns due to an increase of mean value for case and an increase of services. Conclusion: The increase in the efficiency in the utilization of CR Unit leads to an increase of the Hospital efficiency. The transfer of patients from acute units to CR Unit would allow an increased hospitalization rate for acute patients without requiring additional resources.

Cost-Consequence Analysis of Single-Dose Dalbavancin Versus Standard of Care for the Treatment of Acute Bacterial Skin and Skin Structure Infections in a Multisite Healthcare System

2020 ◽  
Author(s):  
Julia Gonzalez ◽  
Diana Carolina Andrade ◽  
JianLi Niu
Keyword(s):  
Healthcare System ◽  
Treatment Success ◽  
Standard Of Care ◽  
Cost Of Care ◽  
Secondary Outcome ◽  
Total Cost ◽  
Skin Structure ◽  
Cost Consequence ◽  
The Difference ◽  
The Cost

Abstract Background Acute bacterial skin and skin structure infections (ABSSSIs) are common infectious diseases that cause a significant economic burden on the healthcare system. This study aimed to compare the cost-effectiveness of dalbavancin vs standard of care (SoC) in the treatment of ABSSSI in a community-based healthcare system. Methods This was a retrospective study of adult patients with ABSSSI treated with dalbavancin or SoC during a 27-month period. Patients were matched based on age and body mass index. The primary outcome was average net cost of care to the healthcare system per patient, calculated as the difference between reimbursement payments and the total cost to provide care to the patient. The secondary outcome was proportion of cases successfully treated, defined as no ABSSSI-related readmission within 30 days after the initiation of treatment. Results Of the 418 matched patients, 209 received SoC and 209 received dalbavancin. The average total cost of care per patient was greater with dalbavancin vs SoC ($4770 vs $2709, P &lt; .0001). The average reimbursement per patient was $3084 with dalbavancin vs $2633 SoC (P = .527). The net cost, calculated as revenue minus total cost, was $1685 with dalbavancin vs $75 with SoC (P = .013). The overall treatment success rate was 74% with dalbavancin vs 85% with SoC (P = .004). Conclusions Dalbavancin was more costly than SoC for the treatment of ABSSSI, with a higher 30-day readmission rate. Dalbavancin does not offer an economic or efficacy advantage.

Sign in / Sign up

Export Citation Format

Share Document